2462 PUBLICATIONS
ANNÉE
JOURNAL
PREMIER AUTEUR
TITRE
ANNÉE2024
JOURNALChembiochem : a European journal of chemical biology
PREMIER AUTEURVaur V
TITREChemical Production of Cytotoxic Bispecific Antibodies Using the Ugi Multicomponent Reaction.
ANNÉE2024
JOURNALCancers
PREMIER AUTEURLebas A
TITREFactors Influencing Long-Term Local Recurrence, Distant Metastasis, and Survival in Patients with Soft Tissue Sarcoma of the Extremities Treated with Radiotherapy.
ANNÉE2024
JOURNALJournal of stomatology, oral and maxillofacial surgery
PREMIER AUTEURBruckmann M
TITREEffectiveness of immune checkpoint inhibitors in the treatment of kidney cancer oral metastasis. A case report.
ANNÉE2024
JOURNALInternational journal of molecular sciences
PREMIER AUTEURCharrière K
TITREExploring the Role of Apigenin in Neuroinflammation: Insights and Implications.
ANNÉE2024
JOURNALCancer science
PREMIER AUTEURChavanton A
TITRELAG-3 : recent developments in combinational therapies in cancer.
ANNÉE2024
JOURNALJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
PREMIER AUTEURLigurgo O
TITREAcute pancreatitis and large cystic pancreatic tumor in an adolescent.
ANNÉE2024
JOURNALCell death & disease
PREMIER AUTEURGiolito MV
TITREImpact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies.
ANNÉE2024
JOURNALCancer medicine
PREMIER AUTEURPetit T
TITRETrastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
ANNÉE2024
JOURNALSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
PREMIER AUTEURDamerval M
TITREAttributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations.
ANNÉE2024
JOURNALRespiratory medicine and research
PREMIER AUTEURMoro-Sibilot D
TITREStudy design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques